Clearline Capital LP Decreases Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Clearline Capital LP cut its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 18.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,810,483 shares of the biotechnology company's stock after selling 416,029 shares during the period. Clearline Capital LP owned about 1.19% of Heron Therapeutics worth $2,770,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in HRTX. Congress Park Capital LLC boosted its stake in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after buying an additional 477,417 shares during the last quarter. Quinn Opportunity Partners LLC acquired a new position in Heron Therapeutics in the fourth quarter valued at approximately $581,000. JPMorgan Chase & Co. boosted its position in Heron Therapeutics by 172.2% in the 4th quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock worth $861,000 after purchasing an additional 356,053 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Heron Therapeutics during the 4th quarter worth approximately $459,000. Finally, CM Management LLC increased its holdings in shares of Heron Therapeutics by 40.0% during the 4th quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock valued at $1,071,000 after purchasing an additional 200,000 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Price Performance

NASDAQ HRTX traded down $0.06 on Friday, hitting $2.11. The company had a trading volume of 1,708,734 shares, compared to its average volume of 2,320,733. The company's fifty day moving average price is $2.19 and its 200-day moving average price is $1.82. The company has a market capitalization of $321.91 million, a PE ratio of -11.72 and a beta of 1.33. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million for the quarter, compared to analyst estimates of $37.08 million. On average, sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.